TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?

Richard J Rebello; Christoph Oing; Silke Gillessen; Robert G Bristow

doi:10.1158/1078-0432.CCR-18-3401

TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?

Clin Cancer Res. 2019 Mar 15;25(6):1699-1701. doi: 10.1158/1078-0432.CCR-18-3401. Epub 2019 Jan 4.

Authors

Richard J Rebello^#¹, Christoph Oing^#^{1

2}, Silke Gillessen^{1

3}, Robert G Bristow⁴

Affiliations

¹ Translational Oncogenomics Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre, Manchester, United Kingdom.
² Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Eppendorf, Hamburg, Germany.
³ Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
⁴ Translational Oncogenomics Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre, Manchester, United Kingdom. [email protected].

^# Contributed equally.

PMID: 30610102
DOI: 10.1158/1078-0432.CCR-18-3401

Abstract

Cell-free circulating tumor DNA (ctDNA) or circulating tumor cell (CTC) assays are potentially powerful in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A new study suggests that mutation of TP53 supersedes AR in predicting mCRPC survival. A role for TP53 mutation as a driver for mCRPC remains unexplored.See related article by De Laere et al., p. 1766.

Publication types

Comment

MeSH terms

Androstenes
Benzamides
Biomarkers, Tumor
Humans
Male
Neoplastic Cells, Circulating*
Nitriles
Phenylthiohydantoin / analogs & derivatives
Prognosis
Prostatic Neoplasms, Castration-Resistant*
Receptors, Androgen
Tumor Suppressor Protein p53

Substances

Androstenes
Benzamides
Biomarkers, Tumor
Nitriles
Receptors, Androgen
TP53 protein, human
Tumor Suppressor Protein p53
Phenylthiohydantoin
enzalutamide
abiraterone